FindTrial
Sign In

Therapeutic outcomes of Empiric Vancomycin in Febrile Neutropenia of Hematologic Malignancy Patients

Therapeutic outcomes of Empiric Vancomycin in Febrile Neutropenia of Hematologic Malignancy Patients

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20221029001
Enrollment
290
Registered
2022-10-29
Start date
2022-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Inpatients with hematologic malignancy who developed febrile neutropenia Febrile neutropenia, Vancomycin, Hematologic malignancy

Interventions

Empirical ATB with Vancomycin,Empirical ATB without Vancomycin
Treatment,Treatment
Vancomycin,non-Vancomycin

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Hematologic malignancy adult patients who admitted in Siriraj hospital 2. Diagnosed as febrile neutropenia as definition of IDSA 2010

Exclusion criteria

Exclusion criteria: 1. Trend to cannot evaluated outcome patient ex. palliative care, against advice

Design outcomes

Primary

MeasureTime frame
Treatment failure 72 hours after empiric antibiotics absence of improvement or deterioration in WBC, BT or SBP and any clinical parameters—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public ContactPornpan Koomanachai

Faculty of Medicine Siriraj Hospital, Mahidol University

nokmed@yahoo.com0819066545

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026